XBXingyao Bu

Xingyao Bu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xingyao Bu has a total of 76 co-authors. Here are the top co-authors by number of shared publications:

  • Yushuai Gao

    Department of Neurosurgery Glioma Engineering Research Center for Precision Diagnosis and Treatment of Henan Province Glioma Clinical Diagnosis and Treatment Center of Henan Province Zhengzhou University People's Hospital Henan Provincial People's Hospital Zhengzhou China

    13 shared publications
  • Meiyun Wang

    Department of Radiology Zhengzhou University People's Hospital Henan University People's Hospital Henan Provincial People's Hospital Zhengzhou China

    12 shared publications
  • Chaojie Bu

    Department of Psychological Medicine Henan Provincial People's Hospital Zhengzhou China

    11 shared publications
  • Guanzheng Liu

    Department of Neurosurgery Glioma Engineering Research Center for Precision Diagnosis and Treatment of Henan Province Glioma Clinical Diagnosis and Treatment Center of Henan Province Zhengzhou University People's Hospital Henan Provincial People's Hospital Zhengzhou China

    11 shared publications
  • Zhaoyue Yan

    Department of Neurosurgery Glioma Engineering Research Center for Precision Diagnosis and Treatment of Henan Province Glioma Clinical Diagnosis and Treatment Center of Henan Province Zhengzhou University People's Hospital Henan Provincial People's Hospital Zhengzhou China

    11 shared publications
  • Zhiyuan Sheng

    Clinical Center for Glioma Henan Provincial People’s Hospital, Henan Province Precision Diagnosis and Treatment Engineering Research Center for Glioma , Zhengzhou

    11 shared publications

Latest Publications

  • Open Access

    Clinical characteristics and prognostic analysis of calcified glioblastoma

    by Mengda Li, Juntao Li, Yongji Guo, Zhixiao Li, Guanzheng Liu, Xingyao Bu, Chunxiao Ma

    Rationale: Glioblastoma (GBM) is a common malignant intracranial tumor. There are a few clinical studies focusing on GBM with calcification. Based on diagnosed cases from our cohort and related literature reports, we investigate its clinical characteristics and diagnosis-treatment strategies. Patient concerns: A retrospective analysis was conducted on the clinical data of 4 patients with pathologically confirmed GBM with calcification admitted between 2017 and 2023. In addition, 5 cases with complete clinical data were identified through a literature review, yielding a total of 9 cases. Based on these cases, we analyzed and discussed the clinical features, treatment strategies, and prognostic outcomes of GBM with calcification in combination with the published literature. Diagnoses: A total of 9 cases of GBM with calcification were included in this study, comprising 4 cases diagnosed in our institution and 5 cases reported in the literature, with an incidence of 0.95%. The median age at diagnosis was 47 years, with a male-to-female ratio of 4:5. Imaging findings were mainly supratentorial lesions, predominantly showing long T1 and long T2 signals, with calcifications appearing as punctate or linear patterns accompanied by significant peritumoral edema, necrosis, and cystic changes. Histologically, all cases demonstrated typical GBM features, with calcification observed in some specimens. Immunophenotypically, Ki-67, Olig-2, and P53 showed high positivity rates. Interventions: Patients who underwent gross total resection had longer survival times than those who underwent partial resection. Outcomes: In terms of prognosis, the median postoperative overall survival time of GBM patients with calcification was 91.32 days, significantly shorter than that of general GBM patients in the same period (570 days). These findings suggest that calcification may be a potential indicator of poor prognosis in GBM. Lessons: The clinical manifestations of GBM patients with calcification have certain characteristics, and the impact of surgery on these patients is different from that on non-calcified GBM. The timing of surgery needs to be carefully selected.

  • Dynamic signature for the effectiveness of anti–PD‐1 therapy combined with vascular normalization therapy in recurrent glioblastoma: A randomized phase 2 trial

    by Jiubing Zhang, Dayang Wang, Guanzheng Liu, Chaojie Bu, Guangming Lv, Minghao Li, Shaobin Wei, Ziyue Zhang, Yushuai Gao, Zhaoyue Yan, et al.

    Background: This study evaluated tislelizumab combined with low‐dose bevacizumab in recurrent glioblastoma (rGBM), assessing efficacy, safety, and mechanisms of immune escape. Methods: This randomized phase 2 trial divided patients into treatment arms with distinct strategies. Longitudinal tumor in situ fluid (TISF) samples were collected for molecular analysis to monitor genome evolution. Immunohistochemical markers in paired primary and recurrent tumor specimens were analyzed to assess therapy‐induced immune resistance. Results: A total of 109 patients were included, with 59 in the control group and 50 in the experimental group. No grade 4 adverse events or treatment discontinuations occurred in the experimental group. The experimental group demonstrated a median overall survival of 13.3 months, compared to 6.6 months in the control group. The objective response rate and disease control rate were 32.6% and 79.1%, respectively. Post‐treatment TISF analysis revealed a 68.4% reduction in detectable genomic alterations. Immunophenotypic analysis of paired tumor samples showed increased infiltration of CD163 + macrophages and elevated GDF‐15 expression in recurrent tumors. Conclusion: This study shows that combining tislelizumab and low‐dose bevacizumab improves survival in rGBM patients with good safety and tolerability. Dynamic changes in TISF‐based molecular markers reflect genomic evolution and predict prognosis. Increased CD163 + cell infiltration in recurrent tumors may activate M2 macrophages, promoting tumor growth and immune evasion. Elevated GDF‐15 levels may further suppress antitumor immunity, facilitating immune escape.


  • Open Access

    Emotional distress impairs immune checkpoint blockade efficacy in recurrent high-grade glioma: Insights from tumor in situ fluid analysis

    by Dayang Wang, Jiubing Zhang, Guanzheng Liu, Chaojie Bu, Shaobin Wei, Minghao Li, Guangming Lv, Zhiyuan Sheng, Jie Mei, Zhaoyue Yan, et al.

    Immune checkpoint blockade (ICB) therapy has shown limited benefit in recurrent high-grade glioma (HGG), in part due to an immunosuppressive tumor microenvironment. Emotional distress (ED) is known to alter immune regulation, yet its role in shaping the response to ICB in glioma remains unexplored. We aimed to determine the association between pre-treatment ED and ICB efficacy in recurrent HGG (rHGG) and to explore the underlying mechanism using tumor in situ fluid circulating tumor DNA (TISF-ctDNA). We prospectively enrolled 75 rHGG patients receiving tislelizumab, bevacizumab, and temozolomide. ED was evaluated using PHQ-9 and GAD-7 before undergoing ICB treatment. Clinical outcomes were compared between ED and No ED groups. TISF-ctDNA sequencing and immunohistochemical staining of tumor tissues were performed to identify pathway alterations and immune markers. Compared to No ED patients, ED patients had significantly shorter overall survival (15.8 vs. 32.3 months; HR = 2.40, P = .006) and progression-free survival (3.4 vs. 7.8 months; P = .049), along with lower objective response (10.7% vs. 48.5%, P = .002) and clinical benefit rates (39.3% vs. 69.7%, P = .017). TISF-ctDNA analysis revealed enrichment of AXON guidance, cAMP signaling, and HPV-related pathways in ED patients. ED was also associated with elevated systemic inflammatory markers (NLR, MLR, PLR; P < .05). IHC showed decreased infiltrating immune cells in tumors from ED patients. Pretreatment ED is associated with impaired ICB efficacy in rHGG, potentially mediated by altered tumor signaling and reduced intratumoral immune cell infiltration. Psychological screening may enhance personalized immunotherapy strategies.


  • Open Access

    Dynamic Tumor in Situ Fluid Circulating Tumor DNA Postsurgery Effectively Predicts Recurrence and Clinical Benefits for Glioblastomas

    by Jiubing Zhang, Guanzheng Liu, Dayang Wang, Chaojie Bu, Guangming Lv, Ziyue Zhang, Guangzhong Guo, Yushuai Gao, Zhaoyue Yan, Chunxiao Ma, et al.

    BACKGROUND AND OBJECTIVES: Glioblastoma (GBM) recurrence after surgery remains a significant clinical challenge because of limited early detection methods and effective molecular markers. This study investigates the potential of dynamic tumor in situ fluid circulating tumor DNA (TISF-ctDNA) as a tool for monitoring molecular residual disease and evaluating treatment efficacy in postsurgical patients with GBM. METHODS: In this prospective cohort study, 75 resectable glioma patients were enrolled between October 2019 to June 2023. Primary tumor tissues and postsurgical TISF samples were collected, along with cranial imaging. TISF-ctDNA was identified through targeted next-generation sequencing, with positivity defined by the presence of one or more variants in the TISF matching those of the primary tumors or an increase of ≥10 single-nucleotide variants across consecutive assessments. RESULTS: TISF-ctDNA positivity was identified in 62.2% of patients in the early postsurgical period, indicating a high prevalence of molecular residual disease. Patients with positive TISF-ctDNA showed a significantly higher risk of recurrence (hazard ratio 2.512, 95% CI 1.264-4.993, P = .0054). Conversion to TISF-ctDNA negativity post-treatment was associated with improved overall survival, highlighting its role in evaluating treatment response. Multivariate analysis revealed that TISF-ctDNA positivity was an independent predictor of progression-free survival during adjuvant therapy, with high predictive accuracy (sensitivity 86.2%, specificity 100%). Importantly, TISF-ctDNA positivity preceded imaging signs of recurrence by a median of 71 days. In this study, no significant impact of specific tumor markers in each subcohort (EGFR, TP53, PTEN, NF1) on progression-free survival or overall survival was observed. CONCLUSION: TISF-ctDNA is a promising biomarker for monitoring GBM recurrence and evaluating clinical benefit. It provides insight into tumor genomic evolution and identifies patients who may benefit from adjuvant chemotherapy. TISF-ctDNA positivity is a robust prognostic indicator for patient outcomes and a marker for molecular recurrence after frontline therapy.


  • Open Access

    Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study

    by Guangzhong Guo, Ziyue Zhang, Jiubing Zhang, Dayang Wang, Sensen Xu, Shuang Wu, Kaiyuan Deng, Yage Bu, Zhiyuan Sheng, Jinliang Yu, et al.

    Background: Glioma recurrence can be divided into in situ recurrence and non‐in situ recurrence, and the mutation evolution of gliomas with different recurrence patterns is still unknown. We used sequential sequencing of circulating tumor DNA (ctDNA) to compare the somatic mutation profile and clonal evolution of gliomas with different recurrence patterns. To investigate the value of ctDNA in predicting early postoperative tumor recurrence and guiding prognosis stratification in patients with glioma.Methods: We prospectively recruited 92 patients with near‐total resection of gliomas from our center. Two hundred and thirty‐four postoperative tissue and Tumor In Situ Fluid (TISF) samples from 69 eligible patients were included in ctDNA analysis.Results: Among the 69 patients, 37 glioblastoma (GBM) patients experienced recurrence, and the median progression‐free survival (mPFS) was not significantly different between the situ recurrence group and the non‐in situ recurrence group (8.6 vs. 6.1 months). The ctDNA of recurrent tissue and TISF were significantly consistent. Before and after initial treatment, TISF‐ctDNA mutant allele fraction (MAF), subclonal mutation, and alterations in related pathways (lysine degradation and PI3K pathway) were negatively correlated with treatment response and PFS. Among recurrent GBM patients, EGFR mutations were the most common. Mutations related to the RTK‐RAS pathway (NF1) were most common in patients with situ recurrent GBM, while mutations in the MUC family and TP53 pathway (MUC16, CHEK2) were prevalent and continuously increased in patients with non‐in situ recurrent GBM.Conclusions: In glioma patients undergoing primary surgery, dynamic monitoring of ctDNA and genotyping can be used for early risk stratification, efficacy monitoring, and early recurrence detection, and provide a basis for clinical research to evaluate early therapeutic intervention.


  • Open Access

    Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab

    by Dayang Wang, Jiubing Zhang, Chaojie Bu, Guanzheng Liu, Guangzhong Guo, Ziyue Zhang, Guangming Lv, Zhiyuan Sheng, Zhaoyue Yan, Yvshuai Gao, et al.

    Purpose Immune checkpoint blockade (ICB) therapies have shown efficacy in various tumors, but long-term responses in glioblastoma are less than 10%. Quantifying tumor in situ fluid circulating tumor DNA (TISF-ctDNA) and therapeutic dynamics may enable real-time GBM disease burden evaluation. This study explores the potential of tumor in situ fluid circulating tumor DNA (TISF-ctDNA) dynamics in predicting treatment efficacy. Methods TISF and peripheral blood samples were collected from patients with recurrent glioblastoma (rGBM) undergoing tislelizumab (a programmed death 1 inhibitor) combined with low-dose bevacizumab (an anti-vascular endothelial growth factor antibody) treatment before and during each immunotherapy cycle. Biomarkers evaluated included TISF-ctDNA, measured using Next Generation Sequencing (NGS), and host inflammation markers such as the platelet-to-lymphocyte ratio (PLR). Results All 32 patients received tislelizumab plus low-dose bevacizumab regularly. The median progression-free survival (PFS) was 4.0 months, and overall survival (OS) was 22.3 months. An analysis of 19 patients with continuous evaluable TISF showed baseline TISF-ctDNA abundance did not correlate with OS (p = 0.23) or PFS (p = 0.23). However, a change in TISF-ctDNA maximal Somatic Variant Allelic Frequency (MVAF) after six treatment cycles predicted both PFS (p = 0.02) and OS (p < 0.0001). Lower baseline PLR also correlated with better survival outcomes. Conclusion The combination of tislelizumab and low-dose bevacizumab therapy appears to be effective in extending both OS and PFS in rGBM patients. Continuous TISF-ctDNA testing shows potential utility in complementing radiological monitoring. The temporal change pattern of TISF MVAF is more predictive of immunotherapy response than imaging. PLR before immunotherapy can screen patients likely to benefit from tislelizumab plus low-dose bevacizumab therapy. Trial registration The trial registration number: NCT05502991; Date of registration: 2022-08-14.


  • Open Access

    Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis

    by Guangzhong Guo, Ziyue Zhang, Jiubing Zhang, Dayang Wang, Sensen Xu, Guanzheng Liu, Yushuai Gao, Jie Mei, Zhaoyue Yan, Ruijiao Zhao, et al.

    Objective: Most recurrent glioblastoma (rGBM) patients do not benefit from immune checkpoint inhibition, emphasizing the necessity for response biomarkers. This study evaluates whether tumor in situ fluid (TISF) circulating tumor DNA (ctDNA) could serve as a biomarker for response to low-dose bevacizumab (Bev) plus anti-PD-1 therapy in rGBM patients, aiming to enhance systemic responses to immunotherapy. Methods: In this phase II trial, 32 GBM patients with first recurrence after standard therapy were enrolled and then received tislelizumab plus low-dose Bev each cycle. TISF samples were analyzed for ctDNA using a 551-gene panel before each treatment. Results: The median progression-free survival (mPFS) and overall survival (mOS) were 8.2 months (95% CI, 5.2–11.1) and 14.3 months (95% CI, 6.5–22.1), respectively. The 12-month OS was 43.8%, and the objective response rate was 56.3%. Patients with more than 20% reduction in the mutant allele fraction and tumor mutational burden after treatment were significantly associated with better prognosis compared to baseline TISF-ctDNA. Among detectable gene mutations, patients with MUC16 mutation, EGFR mutation & amplification, SRSF2 amplification, and H3F3B amplification were significantly associated with worse prognosis. Conclusions: Low-dose Bev plus anti-PD-1 therapy significantly improves OS in rGBM patients, offering guiding significance for future individualized treatment strategies. TISF-ctDNA can monitor rGBM patients' response to combination therapy and guide treatment. Clinical trial registration: This trial is registered with ClinicalTrials.gov, NCT05540275.


  • Open Access

    Tracking tumor evolution during the first-line treatment in brain glioma via serial profiling of cell-free tumor DNA from tumor in situ fluid

    by Zhiyuan Sheng, Chaojie Bu, Jie Mei, Sensen Xu, Ziyue Zhang, Guangzhong Guo, Yushuai Gao, Liyuan Xing, Zhongcan Chen, Juha Hernesniemi, et al.

    Objective: Tumor in situ fluid (TISF) refers to the fluid within surgical cavities of glioma. Several studies preliminarily proved the value of cell-free tumor DNA (cf-tDNA) from TISF in the dynamic characterization of the glioma genome. Here, we assessed the potential utility of TISF cf-tDNA in broad aspects of tumor evolution under therapeutic pressure.Methods: This study was conducted under an Institutional Review Board-approved protocol at Henan Provincial People’s Hospital (China). Cf-tDNA samples were sequenced with a designed 68-gene panel. A total of 205 cf-tDNA samples from 107 patients were studied. The clinical relevance of serial cf-tDNA profiling during the postoperative course was analyzed.Results: At least one tumor mutations were detected in 179/205 (87.3%) TISF cf-tDNA samples. Serial cf-tDNA was complementary to molecular residual disease and to initial tumors. Serial cf-tDNA revealed the selection of pre-existing mismatch repair-deficient cells by temozolomide as a resistant mechanism. Cf-tDNA parameters during treatment were predictive of recurrence, and serial cf-tDNA monitoring had diagnostic value for early recurrence. A total of 223 potentially actionable genomic alterations were assessed in cf-tDNA samples, wherein 78% were not found in any tumor tissue.Conclusions: In conclusion, serial TISF cf-tDNA profiling is valuable in tracking the tumor evolution of glioma during treatment and may be a feasible non-invasive option for monitoring glioma in future prospective studies and clinical practice.


  • Open Access

    Molecular and clonal evolution in vivo reveal a common pathway of distant relapse gliomas

    by Guanzheng Liu, Chaojie Bu, Guangzhong Guo, Zhiyue Zhang, Zhiyuan Sheng, Kaiyuan Deng, Shuang Wu, Sensen Xu, Yage Bu, Yushuai Gao, et al.


  • Open Access

    Genomic alterations of oligodendrogliomas at distant recurrence

    by Guanzheng Liu, Chaojie Bu, Guangzhong Guo, Zhiyue Zhang, Zhiyuan Sheng, Kaiyuan Deng, Shuang Wu, Sensen Xu, Yage Bu, Yushuai Gao, et al.

    Background: Oligodendroglioma is known for its relatively better prognosis and responsiveness to radiotherapy and chemotherapy. However, little is known about the evolution of genetic changes as oligodendroglioma progresses.Methods: In this study, we evaluated gene evolution invivo during tumor progression based on deep whole‐genome sequencing data (ctDNA). We analyzed longitudinal genomic data from six patients during tumor evolution, of which five patients developed distant recurrence.Results: Whole‐exome sequencing demonstrated that the rate of shared mutations between the primary and recurrent samples was relatively low. In two cases, even well‐known major driver mutations in CIC and FUBP1 that were detected in primary tumors were not detected in the relapse samples. Among these cases, two patients had a conversion from the IDH mutation in the originating state to the IDH1 wild state during the process of gene evolution under chemotherapy treatment, indicating that the cell phenotype and genetic characteristics of oligodendroglioma may change during tumor evolution. Two patients received long‐term temozolomide (TMZ) treatment before the operation, and we found that recurrence tumors harbored mutations in the PI3K/AKT and Sonic hedgehog (SHh) signaling pathways. Hypermutation occurred with mutations in MMR genes in one patient, contributing to the rapid progression of the tumor.Conclusion: Oligodendroglioma displayed great spatial and temporal heterogeneity during tumor evolution. The PI3K/AKT and SHh signaling pathways may play an important role in promoting treatment resistance and distant relapse during oligodendroglioma evolution. In addition, there was a tendency to increase the degree of tumor malignancy during evolution. Distant recurrence may be a later event duringoligodendroglioma progression. ClinicalTrials.gov, Identifier: NCT05512325.